{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "BACKGROUND: There is no consensus on optimal management of pilonidal disease."
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "DESIGN: Observational cohort study with nested mixed-methods case study."
      },
      "Participants": {
        "score": 2,
        "evidence": "PARTICIPANTS: Patients aged > 16 years referred for elective surgical treatment of pilonidal disease."
      },
      "Intervention": {
        "score": 1,
        "evidence": "INTERVENTIONS: Surgery."
      },
      "Objective": {
        "score": 1,
        "evidence": "OBJECTIVES: A prospective cohort study to determine: \u2022 disease severity and intervention relationship \u2022 most valued outcomes and treatment preference by patients \u2022 recommendations for policy and future research."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "MAIN OUTCOME MEASURES: Pain postoperative days 1 and 7, time to healing and return to normal activities, complications, recurrence."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Cohort study: Over half of patients (60%; N\u2005=\u2005667) had a major procedure."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "For these procedures, pain was greater on day 1 and day 7 (mean difference day 1 pain 1.58 points, 95% confidence interval 1.14 to 2.01 points, n\u2005=\u2005536; mean difference day 7 pain 1.53 points, 95% confidence interval 1.12 to 1.95 points, n\u2005=\u2005512)."
      },
      "Harms": {
        "score": 1,
        "evidence": "There were higher complication rates (adjusted risk difference 17.5%, 95% confidence interval 9.1 to 25.9%, n\u2005=\u2005579), lower recurrence (adjusted risk difference -10.1%, 95% confidence interval -18.1 to -2.1%, n\u2005=\u2005575)."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "TRIAL REGISTRATION: This trial is registered as ISRCTN95551898."
      },
      "Funding": {
        "score": 1,
        "evidence": "FUNDING: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 17/17/02)."
      }
    },
    "total_score": 13,
    "max_score": 25
  },
  "model": "gpt-4o"
}